Johnson and Johnson Lawsuit Update 2026: Full Case Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

As of September 2, 2026, the biggest shift since this guide was published is that J&J’s talc strategy has moved decisively outside bankruptcy. On July 27, 2026, the company announced a proposed $5.5 billion settlement covering roughly 76,000 ovarian cancer claims across the federal MDL and state courts — a deal negotiated directly with plaintiffs’ attorneys, not through the bankruptcy trust described below. It isn’t final: it takes effect only if law firms representing at least 95% of eligible claimants agree to participate, and it covers ovarian cancer claims only, not mesothelioma. If the threshold is met, resolution is expected within about 18 months, with payments beginning in 2027.

Last updated: September 2026

Johnson and Johnson faces some of the largest ongoing mass tort litigation in U.S. history, and in 2026, multiple active lawsuit tracks are still moving through federal courts. The johnson and johnson lawsuit update 2026 picture is this: J&J’s bankruptcy strategy failed, talc claims are back in civil court, and settlement negotiations are pushing toward resolution across several case types.

Worth reading: Live Olympics Lawsuit 2026: Settlement and Filing Update

This is not a single lawsuit. It is a web of separate legal battles involving baby powder, a psychiatric drug, a children’s pain reliever, and a corporate spin-off. Each track has different eligibility rules, different payout ranges, and different deadlines.

If you used J&J products and experienced a serious health condition, this guide covers what you need to know right now. You will find eligibility breakdowns, payout estimates, court status updates, and filing steps, all in one place.

Roughly 100,000 or more claimants are still seeking compensation across J&J’s active litigation. That number alone tells you this story is far from over.

Johnson and Johnson Lawsuit Update 2026: Where Every Case Stands Right Now

As of 2026, Johnson and Johnson is actively defending multiple major lawsuits simultaneously, and none of them have fully resolved. The talc/asbestos litigation remains the largest, with tens of thousands of claimants pursuing cancer-related claims. A proposed $8.9 billion settlement fund is under ongoing legal challenge in federal courts.

The Risperdal gynecomastia lawsuits have seen verdicts in both directions over the years, but individual trials continue. The Tylenol autism and ADHD cases are progressing through a multidistrict litigation framework. The Kenvue liability question adds another layer of complexity to who exactly claimants are suing.

2026 is shaping up as a pivotal year. Courts are pushing cases toward trial or settlement. Claimants sitting on the sidelines risk losing their window to recover anything.

What Is the Latest Johnson and Johnson Lawsuit News in 2026?

The biggest recent development is that J&J’s third attempt to use the bankruptcy system to cap its talc liability was rejected, and that ruling reshapes everything. Federal appellate courts made clear that a profitable, solvent company cannot use bankruptcy courts to shield itself from mass tort claims.

That means civil litigation is back on the table at full force. Bellwether trials, which are test cases used to gauge how juries respond, are being scheduled again in New Jersey and other jurisdictions.

On the Risperdal front, J&J has already paid out billions in prior settlements and jury verdicts. New trials scheduled for 2026 involve plaintiffs who did not accept earlier offers. On Tylenol, the science debate continues, but claimants’ attorneys argue the MDL court has enough evidence to move forward.

Key 2026 News Headlines:

• Bankruptcy exit route officially closed for talc claims
• New bellwether trial dates set in MDL 2738
• Risperdal cases moving to trial in state courts
• Tylenol MDL judge pressing for trial scheduling order
• Kenvue argues it is not responsible for pre-spin-off liability

Johnson and Johnson Talc Lawsuit 2026: Current Court Status

The talc lawsuit is the centerpiece of J&J’s legal troubles in 2026. It stems from decades of selling talcum powder products, including Johnson’s Baby Powder, that plaintiffs allege contained asbestos fibers and caused ovarian cancer and mesothelioma. J&J disputes this and says its talc was safe and asbestos-free.

MDL 2738, consolidated in the U.S. District Court for the District of New Jersey, continues to manage the bulk of these federal claims. The MDL judge has been pushing both sides toward resolution. With the bankruptcy option gone, J&J is under more direct pressure to either settle or face individual trials.

Trials are expensive and unpredictable for both sides. That pressure is what typically drives mass settlements forward in litigation of this scale.

Johnson and Johnson Baby Powder Lawsuit Settlement 2026: What Claimants Need to Know

J&J pulled Johnson’s Baby Powder from North American shelves in 2020 and from global markets in 2023. That product discontinuation did not end its legal liability. A proposed $8.9 billion settlement was structured to pay claimants over roughly 25 years, but this proposal faced fierce opposition from plaintiff attorneys and claimants who argued it was inadequate.

In 2026, that settlement structure remains under legal challenge. Courts have not given final approval. Some claimants are pushing for higher per-person payouts. Others are pursuing individual trials to get larger verdicts.

What the proposed settlement includes:

• A fund totaling approximately $8.9 billion
• Payments distributed over roughly 25 years
• Structured tiers based on diagnosis type and severity
• Eligibility tied to confirmed use of J&J talc products
• A requirement that claimants release future claims against J&J

The 25-year payout timeline has been one of the most criticized elements. Critics say cancer victims should not wait decades for compensation.

Key Takeaway: J&J’s bankruptcy strategy failed, the talc MDL is back in full civil litigation mode, and the $8.9 billion settlement proposal remains unresolved and contested in 2026.

J&J Talc Ovarian Cancer Lawsuit Update: Which Cancers Qualify?

Ovarian cancer is the primary diagnosis at the center of the talc litigation. Plaintiffs claim that years of using J&J talcum powder in the genital area caused cancerous cells to form in the ovaries. Scientific studies have linked talc use to a modestly elevated ovarian cancer risk, though J&J disputes the causation claims.

Mesothelioma, a rare cancer caused by asbestos exposure, is also a qualifying condition. Some plaintiffs with mesothelioma argue that asbestos fibers in the talc reached lung tissue through inhalation or ingestion.

Qualifying diagnoses in the talc lawsuit:

• Ovarian cancer (any stage)
• Fallopian tube cancer
• Peritoneal cancer (primary)
• Mesothelioma linked to talc asbestos exposure

Diagnoses outside this list generally do not qualify for the talc-specific claims. Other health conditions tied to different J&J products fall under separate lawsuit tracks.

Johnson and Johnson Bankruptcy Lawsuit Update: What Happened to the Texas Two-Step?

The “Texas Two-Step” is a legal maneuver that J&J used by creating a subsidiary, LTL Management LLC, transferring its talc liabilities into that subsidiary, and then filing that subsidiary for bankruptcy. The goal was to freeze all talc lawsuits and force claimants into a bankruptcy settlement process that J&J could control more tightly.

It did not work. The Third Circuit Court of Appeals ruled that LTL Management did not meet the legal standard for financial distress needed to file bankruptcy in good faith. A company cannot manufacture financial trouble to avoid jury trials.

J&J tried this approach three separate times with variations in the strategy. All three attempts ultimately failed.

The failure of this strategy is a significant win for claimants. It means J&J must face traditional civil litigation or negotiate settlements without the protection of bankruptcy court.

Johnson and Johnson Settlement Amount 2026: How Much Is on the Table?

The total proposed talc settlement amount is $8.9 billion, structured over approximately 25 years. This number sounds enormous, but divided across 70,000 or more claimants with a long payment timeline, the individual amounts become more modest.

For Risperdal, J&J has already paid out over $4 billion in judgments and settlements across years of litigation. New Risperdal trials in 2026 could add to that figure. Tylenol settlements have not been finalized as of this writing, and individual payout amounts depend heavily on how courts rule on causation science.

Settlement amount summary by case type:

These numbers represent the outer bounds of what J&J has offered or paid. Individual claimants receive a fraction of the total based on eligibility criteria and tier placement.

Key Takeaway: The total settlement money across all J&J lawsuit tracks reaches into the tens of billions, but individual payouts depend on your specific diagnosis, product use history, and which case track applies to you.

J&J Settlement Payout Per Person 2026: What Could You Actually Receive?

Individual payouts in the J&J talc settlement depend on several factors. Think of it like an insurance claim: the more severe your injury and the stronger your evidence, the more you receive. The proposed settlement uses a tiered system where ovarian cancer with extensive medical documentation sits at the top tier.

Estimates for individual talc claimants range widely. Lower-tier claims may receive anywhere from $20,000 to $100,000. Mid-tier claims involving diagnosed ovarian cancer with confirmed product use may receive $100,000 to $300,000 or more. Mesothelioma claimants, who face the most severe diagnosis, often see the highest payouts, sometimes exceeding $500,000 in individual settlements.

These are estimates based on patterns in similar mass tort settlements. Actual amounts depend on final court-approved distribution formulas.

Risperdal payouts for gynecomastia have ranged from $6,500 to over $680 million in jury verdicts, though most individual settlements land in the tens of thousands.

J&J Risperdal Lawsuit Update 2026: Gynecomastia Claims Still Active

Risperdal is an antipsychotic drug that J&J marketed for off-label uses, including in children and adolescents. Plaintiffs allege that the drug caused boys and young men to develop gynecomastia, which is abnormal breast tissue growth. The FDA issued multiple warnings about this risk, and internal J&J documents showed the company knew about the problem before disclosing it publicly.

J&J paid a $2.2 billion federal settlement in 2013 related to its off-label marketing of Risperdal. But that settlement did not resolve individual injury claims from patients who developed gynecomastia. Those cases have been proceeding through state courts, particularly in Philadelphia, for years.

In 2026, thousands of Risperdal claimants who declined earlier settlement offers are still in line for trials. J&J has been appealing verdicts and negotiating individual resolutions.

Risperdal Lawsuit Key Facts:

A closely related topic: James Henry Lawsuit 2026: Full Settlement and Claim Guide

• Drug: Risperdal (risperidone)
• Manufacturer: Janssen Pharmaceuticals, a J&J subsidiary
• Primary injury claim: Gynecomastia in male minors
• 2013 federal settlement: $2.2 billion for marketing violations
• Individual personal injury claims: Still active in 2026
• Primary venue: Philadelphia Court of Common Pleas

If you or a family member took Risperdal as a minor and developed gynecomastia, your claim may still be eligible, but time-based deadlines vary by state.

Johnson and Johnson Tylenol ADHD Lawsuit 2026: Where Does This Case Stand?

The Tylenol autism and ADHD lawsuit is a separate litigation track from the talc cases. It involves claims that prenatal exposure to acetaminophen (the active ingredient in Tylenol) increased the risk of autism spectrum disorder and ADHD in children born to mothers who used the drug during pregnancy.

This is a scientifically contested area. Studies have shown associations, but causation is debated. The MDL judge handling these cases had previously signaled skepticism about the science, and in late 2023, the court dismissed some claims on Daubert grounds, meaning expert testimony did not meet the standard for admission.

Current 2026 Status:

• The Tylenol MDL is still active but has faced significant legal hurdles
• Some claimants had cases dismissed when certain expert testimony was excluded
• Plaintiffs’ attorneys have been pursuing appeals and presenting alternative experts
• Retailers like Walmart, Walgreens, and CVS were also named as defendants in some claims

This case track is the most legally uncertain of the active J&J lawsuits in 2026. The science hurdle remains the biggest obstacle.

Key Takeaway: Risperdal cases are the most legally settled of J&J’s secondary lawsuit tracks, while the Tylenol autism case faces significant headwinds from scientific admissibility rulings.

Johnson and Johnson Kenvue Lawsuit 2026: Does the Spin-Off Change Anything?

In 2023, Johnson and Johnson spun off its consumer health division, which included the Johnson’s Baby Powder brand, into a separate publicly traded company called Kenvue. J&J retained its pharmaceutical and medical device operations. The question claimants and courts are wrestling with in 2026 is this: who is actually liable for the talc harm?

J&J structured the spin-off in a way that it argues transferred consumer health liabilities to Kenvue. Kenvue, naturally, disputes that it bears full responsibility for conduct that predates its existence as an independent company.

Courts have been sorting through this since the spin-off completed. The general consensus among plaintiff attorneys is that J&J cannot simply hand off decades of liability through a corporate restructuring. J&J maintains indemnification agreements that keep it on the financial hook, but the legal interplay is complex.

Kenvue Spin-Off and Lawsuit Liability:

The short version: suing J&J for talc harm still targets the right company. The Kenvue split adds procedural complexity but has not eliminated J&J’s exposure.

Johnson and Johnson Lawsuit Update 2024 to 2026: A Full Timeline

Understanding where things stand in 2026 requires a quick look back at how the key events unfolded. This timeline covers the major turning points that brought the litigation to its current state.

This timeline shows a company that repeatedly tried to limit its legal exposure through legal architecture and repeatedly lost. The claimants who stayed the course are now closer to actual resolution than ever before.

J&J Lawsuit Who Qualifies 2026: Eligibility Breakdown by Case Type

Eligibility varies significantly depending on which J&J lawsuit track applies to your situation. There is no single universal qualification standard. Each case type has its own requirements tied to the product used, the injury suffered, and the timeline of exposure.

Talc / Baby Powder Claims:

• Used Johnson’s Baby Powder or Shower to Shower talc products
• Diagnosed with ovarian cancer, fallopian tube cancer, peritoneal cancer, or mesothelioma
• Can demonstrate a reasonable timeline of product use before diagnosis
• Typically requires use for a year or more

Risperdal Claims:

• Took Risperdal (risperidone), often during childhood or adolescence
• Developed gynecomastia (breast tissue growth in males)
• Must show documented Risperdal use and medical diagnosis of gynecomastia

Tylenol (Autism/ADHD) Claims:

• Mother used Tylenol during pregnancy
• Child was diagnosed with autism spectrum disorder or ADHD
• Note: This case track faces significant admissibility hurdles in 2026

Age, duration of product use, and medical records all affect the strength of your claim. The earlier you file, the more options you typically have.

J&J Lawsuit Filing Deadline 2026: Do Not Miss These Dates

Filing deadlines in mass tort cases are serious. Missing a statute of limitations or a court-set claims deadline can permanently bar you from receiving compensation, even if you have a strong case. Think of it like a flight: the plane leaves whether or not you are on it.

Each state has its own statute of limitations for personal injury claims. Most states allow 2 to 3 years from the date of discovery of the injury. “Discovery” typically means when you knew or should have known your injury was linked to the product.

General Filing Windows by Claim Type:

2026-specific urgency: Courts overseeing both the talc MDL and Risperdal proceedings have signaled that they will enforce case management order deadlines strictly. Claims submitted after scheduling order cutoffs may not be admitted to the MDL or included in settlement fund distributions.

If you believe you qualify for any J&J lawsuit, 2026 is not the year to wait and see.

How to File a Claim Against Johnson and Johnson in 2026

Filing a claim against Johnson and Johnson in 2026 starts with connecting with a mass tort attorney who handles J&J cases. You do not file directly with J&J or with the court on your own. The process runs through legal counsel who can evaluate your case, gather your medical records, and submit your claim within the correct MDL or state court process.

Here is the general sequence of steps:

Explore this too: Poop Cruise Lawsuit: Who Got Paid and What’s Next 2026

Step 1: Confirm Your Eligibility
Review the qualifying diagnoses and product use requirements above. Gather any receipts, photographs, or other evidence of J&J product use.

Step 2: Gather Medical Records
You will need documented proof of your diagnosis. This includes pathology reports, hospital records, and treating physician notes.

Step 3: Contact a Mass Tort Law Firm
Look for firms with demonstrated J&J litigation experience. Many work on contingency, meaning you pay nothing upfront and they collect a percentage of your settlement.

Step 4: Case Evaluation
Your attorney will review your records, confirm eligibility, and assess the likely value of your claim based on diagnosis and evidence.

Explore this too: Education Lawsuit Last Week: 2026 Payout and Filing Guide

Step 5: Claim Submission
Your attorney files the claim within the appropriate MDL or state court proceeding and tracks it through the litigation process.

The entire pre-filing process typically takes 30 to 90 days when you move quickly. Delays in gathering records are the most common reason claims take longer.

Key Takeaway: You still have the ability to file a J&J lawsuit claim in 2026, but state-specific statutes of limitations and MDL scheduling deadlines make acting sooner significantly better than waiting.

Frequently Asked Questions

Is the Johnson and Johnson lawsuit still active in 2026?

Yes, the Johnson and Johnson lawsuit is still active in 2026.

Multiple lawsuit tracks covering talcum powder, Risperdal, and Tylenol are progressing through federal and state courts right now.

J&J’s bankruptcy strategy to halt the talc litigation was rejected by courts, meaning civil cases are moving forward at full pace.

How much money will J&J pay per person in the 2026 settlement?

Individual payouts in the talc settlement are estimated between $20,000 and $500,000 or more, depending on diagnosis severity.

The higher amounts go to mesothelioma and advanced ovarian cancer claimants with strong medical documentation.

A final settlement formula has not been court-approved yet, so these figures are estimates based on proposed tier structures.

Who qualifies for the Johnson and Johnson talc lawsuit in 2026?

You qualify if you used Johnson’s Baby Powder or Shower to Shower talc products regularly and were diagnosed with ovarian cancer, fallopian tube cancer, peritoneal cancer, or mesothelioma.

You must be able to show a reasonable timeline connecting your product use to your diagnosis.

Medical records documenting your diagnosis are required to move forward with a claim.

What happened to J&J’s bankruptcy strategy in the talc lawsuit?

J&J’s bankruptcy strategy, known as the Texas Two-Step, was rejected three separate times by federal courts.

The Third Circuit Court of Appeals ruled that J&J’s subsidiary, LTL Management LLC, did not meet the legal standard for financial distress required to file bankruptcy in good faith.

The ruling forced J&J back into traditional civil litigation, which is where the talc cases currently stand in 2026.

Can I still file a claim against Johnson and Johnson in 2026?

Yes, you can still file a claim against Johnson and Johnson in 2026, but time is a real factor.

State statutes of limitations typically allow 2 to 3 years from the date you discovered your injury was linked to the product.

MDL scheduling orders in 2026 are creating hard cutoffs for new claims, so filing sooner gives you more options.

The Bottom Line on J&J in 2026

Johnson and Johnson’s legal troubles are not winding down quietly. They are moving toward a genuine reckoning in court. The bankruptcy escape route is gone, the MDLs are active, and claimants who have been waiting years are finally seeing real movement.

If you used J&J talc products and developed ovarian cancer or mesothelioma, your claim window is open right now. The same goes for Risperdal and gynecomastia cases. Start with a mass tort attorney who handles J&J cases and get your medical records together today.

Time is the one thing you cannot recover once it runs out.

Something similar worth reading: Ticketmaster Lawsuit 2026: Updates, Payouts and Claims

A related guide: Carnival Triumph Lawsuit: Full 2026 Payout Updates

A related guide: Reed-Nelson Lawsuit 2026: Settlement and Payout Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.